Literature DB >> 32827851

Synthesis and in vitro anti-bladder cancer activity evaluation of quinazolinyl-arylurea derivatives.

Jia-Nian Chen1, Ting Li2, Li Cheng3, Tai-Sheng Qin4, Ye-Xiang Sun5, Chu-Ting Chen6, Yue-Zhen He7, Guang Liu8, Di Yao9, Ying Wei10, Qiu-Yin Li11, Guang-Ji Zhang12.   

Abstract

Based on the structural modification of molecular-targeted agent sorafenib, a series of quinazolinyl-arylurea derivatives were synthesized and evaluated for their anti-proliferative activities against six human cancer cell lines. Compared with other cell lines tested, T24 was more sensitive to most compounds. Compound 7j exhibited the best profile with lower IC50 value and favorable selectivity. In this study, we focused on 7j-induced death forms of T24 cells and tried to elucidate the reason for its potent proliferative inhibitory activity. Compound 7j treatment could trigger three different cell death forms including apoptosis, ferroptosis, and autophagy; which form would occur depended on the concentrations and incubation time of 7j: (1) Lower concentrations within the initial 8 h of 7j treatment led to apoptosis-dependent death. (2) Ferroptosis and autophagy occurred in the case of higher concentrations combining with extended incubation time through effectively regulating the Sxc-/GPx4/ROS and PI3K/Akt/mTOR/ULK1 pathways, respectively. (3) The above death forms were closely associated with intracellular ROS generation and decreased mitochondrial membrane potential induced by 7j. In molecular docking and structure-activity relationship analyses, 7j could bind well to the active site of the corresponding receptor glutathione peroxidase 4 (GPx4). Compound 7j could be a promising lead for molecular-targeted anti-bladder cancer agents' discovery.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Apoptosis; Autophagy; Ferroptosis; Quinazolinyl-arylurea; Structure-activity relationship

Mesh:

Substances:

Year:  2020        PMID: 32827851     DOI: 10.1016/j.ejmech.2020.112661

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Concise synthesis and biological activity evaluation of novel pyrazinyl-aryl urea derivatives against several cancer cell lines, which can especially induce T24 apoptotic and necroptotic cell death.

Authors:  Jia-Nian Chen; Chu-Ting Chen; Yue-Zhen He; Tai-Sheng Qin; Li Cheng; Ye-Xiang Sun; Kang-Jian Yang; Qi Chen; Chao Yang; Ying Wei
Journal:  RSC Med Chem       Date:  2021-11-11

Review 2.  Regulated cell death (RCD) in cancer: key pathways and targeted therapies.

Authors:  Fu Peng; Minru Liao; Rui Qin; Shiou Zhu; Cheng Peng; Leilei Fu; Yi Chen; Bo Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

3.  A Novel Ferroptosis-Related Gene Model for Overall Survival Predictions of Bladder Urothelial Carcinoma Patients.

Authors:  Min Zhang; Xin Zhang; Minghang Yu; Wei Zhang; Di Zhang; Song Zeng; Xi Wang; Xiaopeng Hu
Journal:  Front Oncol       Date:  2021-07-27       Impact factor: 6.244

Review 4.  Roles of ferroptosis in urologic malignancies.

Authors:  Shankun Zhao; Peng Li; Weizhou Wu; Qinzhang Wang; Biao Qian; Xin Li; Maolei Shen
Journal:  Cancer Cell Int       Date:  2021-12-18       Impact factor: 5.722

5.  Silencing of PFKFB3 protects podocytes against high glucose‑induced injury by inducing autophagy.

Authors:  Zhengming Zhu; Qingsheng Liu; Jianshi Sun; Ziyang Bao; Weiwei Wang
Journal:  Mol Med Rep       Date:  2021-09-07       Impact factor: 2.952

6.  Prognostic value and potential biological functions of ferroptosis-related gene signature in bladder cancer.

Authors:  Yutong Wang; Wenchuan Shao; Yeqi Feng; Junzhe Tang; Qinchun Wang; Dong Zhang; Huaxing Huang; Minjun Jiang
Journal:  Oncol Lett       Date:  2022-07-05       Impact factor: 3.111

7.  Bupivacaine modulates the apoptosis and ferroptosis in bladder cancer via phosphatidylinositol 3-kinase (PI3K)/AKT pathway.

Authors:  Jianli Hao; Weiqing Zhang; Zeqing Huang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.